noiiglutide

Noiiglutide is a novel glucagon-like peptide-1 (GLP-1) receptor agonist developed by Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine Co., and Hengrui Therapeutics. It is a peptide-based drug primarily being investigated for the treatment of type 2 diabetes mellitus and obesity. The drug works by activating the GLP-1 receptor, which plays a crucial role in glucose-dependent insulin secretion, glucagon suppression, and gastric emptying, leading to improved glycemic control and weight loss. Clinical trials have shown its efficacy in reducing blood glucose levels in type 2 diabetes patients and promoting significant weight reduction in obese individuals without diabetes, with a manageable safety profile primarily involving gastrointestinal adverse events.

Other names

noiiglutide-injection